港股异动 | 再鼎医药(09688)涨超9% 公司上市产品快速放量 创新管线逐步收获
再鼎医药(09688)涨超9%，截至发稿，涨9.07%，报22.25港元，成交额6534.51万港元。
华金证券此前研报指出，公司上市产品放量明显，适应症拓展进展顺利。其中，则乐2023H1实现营收0.86亿美元（+35%）。适应症拓展方面，Ⅲ期PRIME数据已于2023年7月公布，与之前临床结果保持一致。此外，国内首款FcRn拮抗剂获批，自免领域适应症布局广泛。
该行续指，公司在研管线丰富，处于临床后期管线达13项。同时，公司拥有差异化的产品管线，未来将有多款重磅产品实现商业化，有望带动业绩快速增长。预计2023-2025年公司将实现营业收入304/477/793百万美元，同比增长42%/57%/66%。
Reprinted from 引领外汇网，the copyright all reserved by the original author.
Disclaimer: The content above represents only the views of the author or guest. It does not represent any views or positions of FOLLOWME and does not mean that FOLLOWME agrees with its statement or description, nor does it constitute any investment advice. For all actions taken by visitors based on information provided by the FOLLOWME community, the community does not assume any form of liability unless otherwise expressly promised in writing.
FOLLOWME Trading Community Website: https://www.followme.com
Hot
No comment on record. Start new comment.